Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib

Bortezomib, in combination with dexamethasone (VD) or with the addition of cyclophosphamide (VCD), is highly effective in patients with amyloid light-chain (AL) amyloidosis. Currently, VCD is considered as a primary regimen for patients with AL, but it is not clear whether the addition of cyclophosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Kastritis, E, Gavriatopoulou, M, Roussou, M, Fotiou, D, Ziogas, D C, Migkou, M, Eleutherakis-Papaiakovou, E, Panagiotidis, I, Kanellias, N, Psimenou, E, Papadopoulou, E, Pamboucas, C, Manios, E, Gakiopoulou, H, Ntalianis, A, Tasidou, A, Giannouli, S, Terpos, E, Dimopoulos, M A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520394/
https://www.ncbi.nlm.nih.gov/pubmed/28622303
http://dx.doi.org/10.1038/bcj.2017.47

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520394/
https://www.ncbi.nlm.nih.gov/pubmed/28622303
http://dx.doi.org/10.1038/bcj.2017.47

Ejemplares similares